Characterization of single-nucleotide polymorphisms relevant to inflammatory bowel disease in commonly used gastrointestinal cell lines

Inflammatory Bowel Diseases

Volumn 16, Issue 2, 2010, Pages 282-295

  Huebner, Claudia ^a,b   Petermann, Ivonne ^a,b   Lam, Wen Jiun ^a,b   Shelling, Andrew N ^a   Ferguson, Lynnette R ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Nutrigenomics New Zealand   (New Zealand)

Author keywords

Cancer; Gastrointestinal cell lines; Inflammatory bowel disease (IBD); Single nucleotide polymorphisms (SNPs)

Indexed keywords

ARTICLE; CELL LINE; CHROMOSOME ABERRATION; CONTROLLED STUDY; ENTERITIS; GENE EXPRESSION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; CACO-2 CELLS; CELL LINE; CHROMOSOME ABERRATIONS; GENE EXPRESSION PROFILING; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HCT116 CELLS; HT29 CELLS; HUMANS; INFLAMMATORY BOWEL DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 73949141543     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21043     Document Type: Article

References (87)

1. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-678.
2. Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology. 2003;124:993-1000.
3. Inoue M, Takata H, Ikeda Y, et al. A promoter polymorphism of the alpha2-HS glycoprotein gene is associated with its transcriptional activity. Diabetes Res Clin Pract. 2008;79:164-170.
4. Rokavec M, Justenhoven C, Schroth W, et al. A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk. Clin Cancer Res. 2007;13:7506-7514.
5. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988;48:589-601.
6. Urban TJ, Gallagher RC, Brown C, et al. Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5). Mol Pharmacol. 2006;70:1602-1611.
7. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525-528.
8. Kwan T, Benovoy D, Dias C, et al. Genome-wide analysis of transcript isoform variation in humans. Nat Genet. 2008;40:225-231.
9. Landi D, Gemignani F, Naccarati A, et al. Polymorphisms within micro-RNA binding sites and risk of sporadic colorectal cancer. Carcinogenesis. 2008;29:579-584.
10. Wang XB, Pirskanen R, Giscombe R, et al. Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. J Intern Med. 2008;263:61-69.
11. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut. 2004;53:987-992.
12. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473-3478.
13. Borm ME, van Bodegraven AA, Mulder CJ, et al. A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet. 2005;32:401-405.
14. Brant SR, Panhuysen CI, Nicolae D, et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet. 2003;73:1282-1292.
15. Browning BL, Huebner C, Petermann I, et al. Association of DLG5 variants with inflammatory bowel disease in the New Zealand caucasian population and meta-analysis of the DLG5 R30Q variant. Inflamm Bowel Dis. 2007;13:1069-1076.
16. Dambacher J, Staudinger T, Seiderer J, et al. Macrophage migration inhibitory factor (MIF)-173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. Inflamm Bowel Dis. 2007;13:71-82.
17. Cummings JR, Cooney R, Pathan S, et al. Confirmation of the role of ATG16L1 as a Crohn's disease susceptibility gene. Inflamm Bowel Dis. 2007;13:941-946.
18. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet. 2007;39:830-832.
19. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 2004;36:476-480.
20. Torok HP, Glas J, Tonenchi L, et al. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology. 2004;127:365-366.
21. Abdel-Rahman WM, Katsura K, Rens W, et al. Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. Proc Natl Acad Sci U S A. 2001;98:2538-2543.
22. Dutrillaux B. Pathways of chromosome alteration in human epithelial cancers. Adv Cancer Res. 1995;67:59-82.
23. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643-649.
24. Bekpen C, Hunn JP, Rohde C, et al. The interferon-inducible p47 (IRG) GTPases in vertebrates: loss of the cell autonomous resistance mechanism in the human lineage. Genome Biol. 2005;6:R92.
25. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699-5708.
26. Leushner J, Chiu NH. Automated mass spectrometry: a revolutionary technology for clinical diagnostics. Mol Diagn. 2000;5:341-348.
27. A haplotype map of the human genome. Nature. 2005;437:1299-1320.
28. Annese V, Palmieri O, Latiano A, et al. Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease Study. Dig Liver Dis. 2004;36:121-124.
29. Huebner C, Petermann I, Browning BL, et al. Triallelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677/T/A as an example. Cancer Epidemiol Biomarkers Prev. 2007;16:1185-1192.
30. Browning BL, Huebner C, Petermann I, et al. Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol. 2007;102:2504-2512.
31. Ferguson LR, Huebner C, Petermann I, et al. Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk. World J Gastroenterol. 2008;14:4652-4661.
32. Gearry RB, Richardson A, Frampton CM, et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis. 2006;12:936-943.
33. Gazouli M, Mantzaris G, Kotsinas A, et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol. 2005;11:681-685.
34. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001;357:1925-1928.
35. Klein W, Tromm A, Folwaczny C, et al. A polymorphism of the bactericidal/permeability increasing protein (BPI) gene is associated with Crohn's disease. J Clin Gastroenterol. 2005;39:282-283.
36. Klein W, Tromm A, Folwaczny C, et al. The G2964A polymorphism of the STAT6 gene in inflammatory bowel disease. Dig Liver Dis. 2005;37:159-161.
37. Klein W, Tromm A, Folwaczny C, et al. A polymorphism of the NFKBIA gene is associated with Crohn's disease patients lacking a predisposing allele of the CARD15 gene. Int J Colorectal Dis. 2004;19:153-156.
38. Klein W, Tromm A, Griga T, et al. A polymorphism in the CD14 gene is associated with Crohn disease. Scand J Gastroenterol. 2002;37:189-191.
39. McGovern DP, Hysi P, Ahmad T, et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet. 2005;14:1245-1250.
40. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet. 2004;36:471-475.
41. Sashio H, Tamura K, Ito R, et al. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively. Immunogenetics. 2002;53:1020-1027.
42. Hubacek JA, Rothe G, Pit'ha J, et al. C(-260)->T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation. 1999;99:3218-3220.
43. Unkelbach K, Gardemann A, Kostrzewa M, et al. A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol. 1999;19:932-938.
44. Bernig T, Chanock SJ. Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Rev Mol Diagn. 2006;6:319-331.
45. Belley A, Keller K, Grove J, et al. Interaction of LS174T human colon cancer cell mucins with Entamoeba histolytica: an in vitro model for colonic disease. Gastroenterology. 1996;111:1484-1492.
46. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology. 2007;132:1359-1374.
47. Moehle C, Ackermann N, Langmann T, et al. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med. 2006;84:1055-1066.
48. Panigrahi P, Braileanu GT, Chen H, et al. Probiotic bacteria change Escherichia coli-induced gene expression in cultured colonocytes: implications in intestinal pathophysiology. World J Gastroenterol. 2007;13:6370-6378.
49. Peterson JW, Dickey WD, Saini SS, et al. Phospholipase A2 activating protein and idiopathic inflammatory bowel disease. Gut. 1996;39:698-704.
50. Rosenstiel P, Fantini M, Brautigam K, et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology. 2003;124:1001-1009.
51. Seiderer J, Dambacher J, Kuhnlein B, et al. The role of the selenoprotein S (SELS) gene-105G>A promoter polymorphism in inflammatory bowel disease and regulation of SELS gene expression in intestinal inflammation. Tissue Antigens. 2007;70:238-246.
52. Ying L, Hofseth AB, Browning DD, et al. Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation. Cancer Res. 2007;67:9286-9293.
53. Ghadimi BM, Sackett DL, Difilippantonio MJ, et al. Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer. 2000;27:183-190.
54. Leung WK, Kim JJ, Wu L, et al. Identification of a second MutL DNA mismatch repair complex (hPMS1 and hMLH1) in human epithelial cells. J Biol Chem. 2000;275:15728-15732.
55. Masramon L, Ribas M, Cifuentes P, et al. Cytogenetic characterization of two colon cell lines by using conventional G-banding, comparative genomic hybridization, and whole chromosome painting. Cancer Genet Cytogenet. 2000;121:17-21.
56. Melcher R, Koehler S, Steinlein C, et al. Spectral karyotype analysis of colon cancer cell lines of the tumor suppressor and mutator pathway. Cytogenet Genome Res. 2002;98:22-28.
57. Tsushimi T, Noshima S, Oga A, et al. DNA amplification and chromosomal translocations are accompanied by chromosomal instability: analysis of seven human colon cancer cell lines by comparative genomic hybridization and spectral karyotyping. Cancer Genet Cytogenet. 2001;126:34-38.
58. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187-191.
59. Bonen DK, Ogura Y, Nicolae DL, et al. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology. 2003;124:140-146.
60. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
61. Kuballa P, Huett A, Rioux JD, et al. Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant. PLoS ONE. 2008;3:e3391.
62. Chen TR, Hay RJ, Macy ML. Karyotype consistency in human colorectal carcinoma cell lines established in vitro. Cancer Genet Cytogenet. 1982;6:93-117.
63. Kallioniemi OP, Kallioniemi A, Piper J, et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer. 1994;10:231-243.
64. Vermeulen SJ, Chen TR, Speleman F, et al. Did the four human cancer cell lines DLD-1, HCT-15, HCT-8, and HRT-18 originate from one and the same patient? Cancer Genet Cytogenet. 1998;107:76-79.
65. Camps J, Armengol G, del Rey J, et al. Genome-wide differences between microsatellite stable and unstable colorectal tumors. Carcinogenesis. 2006;27:419-428.
66. Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558-561.
67. Ribas M, Masramon L, Aiza G, et al. The structural nature of chromosomal instability in colon cancer cells. FASEB J. 2003;17:289-291.
68. Gayet J, Zhou XP, Duval A, et al. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene. 2001;20:5025-5032.
69. Pabst O, Schneider A, Brand T, et al. The mouse Nkx2-3 homeodomain gene is expressed in gut mesenchyme during pre- and postnatal mouse development. Dev Dyn. 1997;209:29-35.
70. Canny G, Levy O, Furuta GT, et al. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A. 2002;99:3902-3907.
71. Huttner KM, Bevins CL. Antimicrobial peptides as mediators of epithelial host defense. Pediatr Res. 1999;45:785-794.
72. Ouellette AJ. Defensin-mediated innate immunity in the small intestine. Best Pract Res Clin Gastroenterol. 2004;18:405-419.
73. Wehkamp J, Schmid M, Fellermann K, et al. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol. 2005;77:460-465.
74. Ferguson LR, Browning BL, Huebner C, et al. Single nucleotide polymorphisms in human Paneth cell defensin A5 may confer susceptibility to inflammatory bowel disease in a New Zealand Caucasian population. Dig Liver Dis. 2008;40:723-730.
75. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6:813-823.
76. Nakumura T, Sakaeda T, Ohmoto N, et al. Gene expression profiles of ABC transporters and cytochrome P450 3A in Caco-2 and human colorectal cancer cell lines. Pharm Res. 2003;20:324-327.
77. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal. 2001;13:85-94.
78. Funda DP, Tuckova L, Farre MA, et al. CD14 is expressed and released as soluble CD14 by human intestinal epithelial cells in vitro: lipopolysaccharide activation of epithelial cells revisited. Infect Immun. 2001;69:3772-3781.
79. Ohashi R, Tamai I, Nezu Ji J, et al. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001;59:358-366.
80. Wu X, Huang W, Prasad PD, et al. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999;290:1482-1492.
81. Burwinkel B, Kreuder J, Schweitzer S, et al. Carnitine transporter OCTN2 mutations in systemic primary carnitine deficiency: a novel Arg169Gln mutation and a recurrent Arg282ter mutation associated with an unconventional splicing abnormality. Biochem Biophys Res Commun. 1999;261:484-487.
82. Wang Y, Korman SH, Ye J, et al. Phenotype and genotype variation in primary carnitine deficiency. Genet Med. 2001;3:387-392.
83. Wang Y, Ye J, Ganapathy V, et al. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc Natl Acad Sci U S A. 1999;96:2356-2360.
84. Grube M, Meyer zu Schwabedissen HE, Prager D, et al. Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation. 2006;113:1114-1122.
85. Mickley LA, Lee JS, Weng Z, et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood. 1998;91:1749-1756.
86. Nakamura T, Sakaeda T, Horinouchi M, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002;71:297-303.
87. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol. 2007;8:931-937.